We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.
- Authors
Botta, Cirino; Martino, Enrica Antonia; Conticello, Concetta; Mendicino, Francesco; Vigna, Ernesto; Romano, Alessandra; Palumbo, Giuseppe Antonio; Cerchione, Claudio; Martinelli, Giovanni; Morabito, Fortunato; Di Raimondo, Francesco; Gentile, Massimo
- Abstract
Keywords: myeloma; network meta analysis; daratumumab; lenalidomide; bortezomib; carfilzomib; isatuximab EN myeloma network meta analysis daratumumab lenalidomide bortezomib carfilzomib isatuximab N.PAG N.PAG 4 04/26/21 20210414 NES 210414 Introduction Over the past 10 years, the treatment of multiple myeloma (MM) dramatically changed due to the introduction of a number of new agents and combination regimens both in the frontline and in the relapsed/refractory setting. All the groups were well balanced for presence of lena-refractory patients (about 70%, with the exception of the Castor trial which, within the lena-exposed population, only included about 50% of lena-refractory patients), exposure to bortezomib (about 65%, with the exception of the aCD38 KD group were about 90% of patients have been previously exposed to bortezomib) ( B Table 1 b ) and patients treated in second line (about 45% in all trials, data not shown). Evidence from Clinical Trials Overall, we included 1,616 relapsed refractory MM patients (RR/MM) previously exposed to lenalidomide (lena-exposed) and 984 RR/MM patients reported to be lenalidomide refractory (lena-refractory) included in six randomized phase 3 trials ([5]-[10]).
- Subjects
MULTIPLE myeloma; SUPPRESSOR cells
- Publication
Frontiers in Oncology, 2021, Vol 11, pN.PAG
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2021.643490